SANS PRĖCĖDENT - TWO LEGENDS EXPLORE ONE OF THE WORLD'S MOST RESPECTED VARIETALS
ADELAIDE, Australia, Feb. 9, 2025 /PRNewswire/ -- Introducing Grange La Chapelle 2021, the result of curiosity and exploration that united cultures across two hemispheres. A blend that truly intertwines the rich heritage of French wine tradition and the innovative spirit of Australian craft.
A long-standing friendship between Caroline Frey, Chief Winemaker and vigneron, La Chapelle and Peter Gago, Chief Winemaker Penfolds Grange enabled this unexpected union to showcase what this varietal can achieve aromatically and structurally - coalescing different geographies, different soils and different winemaking cultures. Caroline and Peter both acknowledge that after many conversations, the time was right to work together.
This partnership created a pure varietal expression of equal parts in harmony. 50% La Chapelle France, from the steep, sun drenched slopes of the Hill of Hermitage and 50% Grange made from a collection of select South Australian vineyards: Barossa Valley, McLaren Vale, Clare Valley - including many old 19th-Century vines from a State that has never been scourged by phylloxera. It combines the attributes of French Syrah and Australian Shiraz, expressions that share a common ancestry yet have evolved into distinctive styles from their respective terroirs. A new wine different and yet respectful of parentage and original DNA - bravely using the flagship wine of both … not without risk.
Grange La Chapelle has its own identity. It is bold, yet elegant, structured yet expressive, offering a unique experience showcasing two legends. Caroline Frey said, 'As the project progressed, I saw the elegance in Grange and the strength in La Chapelle.'
This blend offers a true taste of the shared history of Syrah and Shiraz and future possibilities. While this is the first inaugural vintage release (2021), this wine is intended for future release, mother nature permitting - annually.
Peter Gago said, 'When things are real, all quickly becomes self-evident … This friendship created an idea, this idea became a trial, the trial became a wine. Who would have thought …" Peter goes on to reference earlier links, including a major La Chapelle and Grange tasting organised by The Institute of Masters of Wine many years back. More recently in 1987, a Hermitage Luncheon at Rakel Restaurant in New York (with a young chef, Thomas Keller!) co-hosted by Gerard Jaboulet and Max Schubert. Pouring the 1971 Penfolds Grange and 1978 Jaboulet Hermitage La Chapelle – certainly a celebration of Syrah and Shiraz. Fast-forward 38 years to 2025 and this connection has now come full-circle.
Eighteen customers from around the world were personally invited by both teams sensitively to hand sell Grange La Chapelle 2021 to their private customers. The wine is rare, and the make size small. A small allocation will be sold by Penfolds direct to consumer channel in Australia, and the USA.
Grange La Chapelle 2021 was celebrated at the inaugural global launch in Paris on February 9, 2025, at an intimate invite only Black-Tie evening hosted by Caroline Frey and Peter Gago, at Monnaie de Paris.
750ml RRP Australia AUD: $3,500 | 750ml RRP France €2,600. Visit grangexlachapelle.com for further information.
NOTES TO EDITOR:
About Grange La Chapelle:
Bold and unique. Uniting winemaking cultures, spanning hemispheres and time. Fate. A longstanding friendship between two winemakers created an idea. The idea became a trial. The trial became a wine. And then there were three – 2021 (bottled), 2022 (bottled) and 2023 (in barrel). Who would have thought? Syrah from the legendary Hill of Hermitage, La Chapelle, coupled with Shiraz from esteemed South Australian vineyards, Grange. The blend's raison d'être: One variety - reunited, reinterpreted, reassembled. La Chapelle named after the chapel on the top of the mound of granite on the left bank of Rhône, is a revered wine in Tain l'Hermitage, France. This Syrah from the revered Hermitage appellation is both powerful & mythical, made to last. Today La Chapelle vintages 1978, 1990, 1991 & 2015 vintages are much sought after globally, and the 1961 remains a 20th-Century wine legend.
Grange is named after the cottage at Magill Estate Winery South Australia (originally established by early settlers Dr Penfold and his wife Mary in 1844). Created in 1951, Grange has enjoyed a consecutive annual release for more than 70 years, and is also highly respected and endorsed by wine cognoscenti around the world. Prized vintages to relish today include 1952, 1962, 2008, 2010 & 2018
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
10 minutes ago
- Associated Press
Libertas Bio, a Formation Bio subsidiary, License of Gusacitinib, a Dual JAK/SYK Inhibitor, to Sanofi
NEW YORK, June 23, 2025 /PRNewswire/ -- Formation Bio, an AI-native pharma company focused on accelerating drug development, today announced that its subsidiary Libertas Bio has licensed gusacitinib, an oral dual JAK/SYK inhibitor, to Sanofi. Sanofi will explore its potential in a new indication not previously studied through a phase 1 study. Gusacitinib was acquired by Formation Bio (formerly known as TrialSpark) in late 2022 from Asana BioSciences as part of a broader portfolio of investigational medicines. This transaction with Sanofi ushers gusacitinib into its next stage of development, with Sanofi leveraging its global expertise in drug development and commercialization to explore its potential in new indications. This transaction exemplifies Formation Bio's differentiated business model: identifying and acquiring high-potential clinical-stage assets. Formation Bio and Sanofi have several long-standing collaborations focused on identifying high-potential assets and co-developing AI tools that leverage shared data and technical expertise. This latest transaction builds on that collaboration, further strengthening both companies' commitment to advancing promising therapies through innovative technology and scientific excellence. Benjamine Liu, Co-Founder & CEO of Formation Bio, commented: 'Formation Bio is redefining drug development through radical efficiency at every step. We acquire high-potential assets, move quickly to unlock value, and partner at key inflection points. We're proud to have Sanofi as a world-class partner working together to accelerate innovation in medicine.' About Formation Bio Formation Bio is an AI-native pharma company differentiated by radically more efficient drug development. Formation Bio has built technology and AI platforms, processes, and capabilities to accelerate all aspects of drug development and clinical trials. Formation Bio partners, acquires, or in-licenses drugs from pharma companies and biotechs to develop programs past clinical proof of concept and beyond, leveraging their proprietary tech and AI capabilities, ultimately helping to bring new medicines to patients. For more information, please visit Media Contact: [email protected] View original content to download multimedia: SOURCE Formation Bio
Yahoo
11 minutes ago
- Yahoo
New Study Reveals AI Adoption in Healthcare Payments Reaches Strategic Inflection Point
Study finds AI is delivering double-digit gains in revenue cycle performance, becoming indispensable to healthcare providers' success LEHI, Utah and LOUISVILLE, Ky., June 23, 2025 /PRNewswire/ -- Waystar (Nasdaq: WAY), a provider of leading healthcare payment software, today announced the results of a commissioned study conducted by Forrester Consulting on behalf of Waystar revealing that AI is becoming mission-critical in revenue cycle management (RCM) because of its proven impact and measurable return on investment. The study, "AI in Healthcare Payments Software: A Strategic Imperative," shows that 82% of healthcare leaders now consider AI integral to their RCM operations, with 70% identifying it as a top organizational priority. The study also found that AI is delivering significant improvements in key revenue cycle metrics, including claim accuracy, denial prevention, workforce efficiency, and payment speed, signaling a sharp acceleration in healthcare's AI adoption curve. "This research reinforces what we're seeing across the industry. AI is no longer theoretical and is fundamentally reshaping how providers operate," said Matt Hawkins, CEO of Waystar. "As healthcare organizations navigate growing complexity, the study shows they're relying on proven and trusted RCM software providers to deploy AI." Key findings include: AI is yielding 13-37% improvements in high-impact revenue cycle areas. These capabilities consistently exceed expectations for enhancing performance and automating critical processes, such as claim follow-up, payment accuracy, denial prevention, and workforce efficiency. Trust in AI is accelerating, with 60% of decision-makers reporting that their confidence has increased since implementation. Firsthand experience is quickly building trust in AI's accuracy and its ability to transform the revenue cycle. The majority of healthcare decision makers who were initially skeptical now say their concerns have significantly decreased or disappeared. 82% of healthcare leaders say AI is now an integral part of their revenue cycle operations, reflecting growing trust and proven impact. Nearly 70% view AI as a high or critical organizational priority, and 60% plan to increase AI investment, underscoring its strategic role in driving payment performance and process transformation. The majority of healthcare leaders are turning to existing RCM software partners for AI capabilities, citing faster time to value, proven integration, and established data security protocols. Onboarding new-to-market AI vendors remains the least common path, highlighting the preference for trusted, integrated platforms. Based on responses from more than 300 healthcare leaders, the study shows that providers are prioritizing strategic AI implementation, especially in payer-facing workflows such as prior authorizations and denial appeals. The research points to a broader shift as AI delivers measurable impact across organizations of all sizes, accelerating automation, enhancing analytics, improving accuracy, and driving stronger returns on investment. To view the full study, visit About Waystar Waystar's mission-critical software is purpose-built to simplify healthcare payments so providers can prioritize patient care and optimize their financial performance. Waystar serves approximately 30,000 clients, representing over 1 million distinct providers, including 16 of 20 institutions on the U.S. News Best Hospitals list. Waystar's enterprise-grade platform annually processes over 6 billion healthcare payment transactions, including over $1.8 trillion in annual gross claims and spanning approximately 50% of U.S. patients. Waystar strives to transform healthcare payments so providers can focus on what matters most: their patients and communities. Discover the way forward at Media Contact Kristin Lee View original content to download multimedia: SOURCE Waystar Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
21 hours ago
- Yahoo
Cyberway Product Innovation Platform: Empowering Enterprise Innovation Processes and Building Exceptional Product Strength
GUANGZHOU , June 22, 2025 /PRNewswire/ -- In the fiercely competitive FMCG market, only efficient innovation can create a true competitive edge. As consumer preferences change rapidly and the market environment remains uncertain, how can companies precisely identify needs, execute efficiently, and continuously optimize their strategies? The Cyberway Product Innovation Platform empowers FMCG enterprises to achieve sustainable growth by providing powerful capabilities in pre-planning insight, in-process control, and post-launch analytics—ultimately enabling the development of exceptional product strength. Before: AI-Powered Foresight for Accurate Market Opportunity Detection AI Opportunity Discovery: Real-time industry data, user behavior, and competitor insights are captured to automatically identify blue ocean markets and unmet needs—fueling inspiration for new product planning. Accelerate Opportunity Capture: Shorten market research cycles and improve speed and accuracy of opportunity identification. AI-Driven Product Definition: Using opportunity and competitor analysis, combined with internal product knowledge bases, the system intelligently generates product concepts, optimizes configurations, and refines packaging and formulas. Agile Response: Ensure product design closely aligns with market needs and competition, allowing rapid focus on core value and improving product-market fit. End-to-End User Demand Management: A comprehensive demand management framework tracks records, statuses, and feedback, aggregating omnichannel voice of customer with AI to identify high-value & Accurate: By realizing and verifying demand in closed-loop cycles, continuously refine product performance, minimize resource waste, and pave the way for the next breakout product. During: Efficient Execution to Deliver Outstanding Products Scientific Project Management System: Integrates visual dashboards, all-in-one workbenches, and real-time notifications via Feishu, WeCom, and DingTalk for full project transparency and synchronized decision-making across teams. Core Value: Reduce communication overhead, improve collaboration efficiency, and prevent project delays. Standardized Project Workflow: Based on industry templates and task libraries, enabling tiered and structured project management tailored to channel requirements. Flexible Control: Guarantees high-quality delivery while allowing adaptive workflows, ensuring key tasks succeed the first time. Cross-Functional Online Collaboration: Integrates marketing, go-to-market, and product workflows to shorten timelines. Interlocked nodes require mutual confirmation to ensure stability and avoid cost waste. Key Feature: Enables synergistic cooperation across departments for performance greater than the sum of its parts. AI Marketing: Tracks competitor strategies and social trends in real time, dynamically generating targeted content and pricing strategies using internal knowledge. Efficient & Agile: Accelerates creative production and drives an integrated "strategy-content-pricing" engine for rapid market response. Online Knowledge Repository: A dedicated enterprise R&D knowledge base aggregating key data such as risk warnings, solutions, and technical documentation. Significant Boost: Empowers faster troubleshooting and prevents redundant errors in R&D. Comprehensive Quality Control System: Embeds IPD checkpoints and technical reviews to govern key milestones; incorporates risk management for prevention, monitoring, and post-analysis. Ultimate Goal: Ensure high-quality project delivery while minimizing potential risks. After: Data-Driven Innovation Strategy Optimization Project Review: Compare project baselines with actual execution to deeply analyze quality, timeline, and cost performance. Deeper Insights: Identify key factors that influence project success. Go-to-Market Tracking: Monitor GMV trends across e-commerce platforms, VOC on social media, and promotional campaign outcomes to pinpoint growth opportunities and risks, driving agile strategy iteration. Advanced Capabilities: Fuel product iteration and innovation, providing a core foundation for the next-generation breakout product. Data Asset Management: Leverages delivery data and gate review points to auto-update master product data, creating a unified view with field supplementation and relationship validation. Long-Term Value: Enables full-lifecycle product data management, enhancing both data quality and business utility. The Cyberway Product Innovation Collaboration Platform is a powerful enabler for FMCG enterprises to enhance product innovation with AI, reduce waste, shorten R&D cycles, and create market bestsellers. From ideation to launch and ongoing optimization, the platform empowers excellence at every stage—allowing businesses to stand out in an intensely competitive landscape. We look forward to partnering with more brands to explore new ways of innovation and co-create the next market blockbuster! Website: Email：Marketing@ View original content: SOURCE Cyberway Information Technology Co., Ltd. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
